InvestorsHub Logo
Followers 1
Posts 261
Boards Moderated 0
Alias Born 09/11/2017

Re: lesgetrich post# 3070

Tuesday, 09/12/2017 10:39:29 AM

Tuesday, September 12, 2017 10:39:29 AM

Post# of 9998
Good points noted. My concern is that EB itself is categorized as a rare disorder only affecting something like 1 out of 20,000. That said the market cap for any EB treatment/cure is relatively small when compared to drugs catered to a much larger target market. Perhaps they (Abeona and IMLFF) have some potential within the same small space, but I'd be more confident if IMLFF's INM-750 was much further along with respect to clin trials. I personally think that it won't be the drugs (INM-750) or others in their pipeline that will make this a banner company, but finding a way to monetize the bioinformatics technology. That's why I'm personally intrigued by them.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INM News